Дослідження матеріалів для референтних міток для променевої терапії

Actuality: for the treatment of malignant diseases radiotherapy is used, we receive accurate anatomical information of the biological properties of the tumor at the stage of topometric preparation of patients with reference X-ray contrast labels which are expensive and in limited quantities. Purpose: the development of special X-ray contrast labels to improve the quality of anatomical and topographic sections using computer tomography (CT). Tasks: 1. Conduct a literary review of all X-ray contrast materials used in medicine and conduct a comparative evaluation of materials; 2. Investigate the behavior of the material during the CT for its immediate use in 2D, 2D + and 3D computer programming; 3. To substantiate the choice of the material of X-ray contrast labels and to investigate the dependence of the size of the desired marker on the volume of the tumor; 4. Design a marker with SolidWorks; 5. Investigate different types of tag attachment to the patient's body and choose the most effective one. Main results: a literary review of X-ray contrast materials used in medicine was carried out, a comparative evaluation of the materials was carried out, the behavior of the materials during the CT was investigated; the best material for X-ray contrast markers was selected and the best form of labels was selected, the dependence of the size of the marker on the volume of the tumor was studied; A marker was constructed using SolidWorks, various ways of fixing labels to the patient's body and choosing the most effective one were studied

National Case Studies on Health Policy-making in the Middle East: The Case of the National Social Security Fund Voluntary Health Insurance System in Lebanon

Summary Brie

MasterMindGenesis™ — Foundational IP, Patents & Scientific Validation

“This umbrella OSF project serves as the official, timestamped public archive for all core intellectual property (IP), patents, peer reviews, scientific validation, and legal evidence related to the MasterMindGenesis™ invention suite (including MindAmp FX, GULF Law, HFML™, ISOTruth™, Silent Human Resonance™, AuraShield™, Tunable Reality™ and associated trademarks). All uploads are intended for legal defensibility, scholarly citation, and public transparenc

MasterMindGenesis™ — Foundational IP, Patents & Scientific Validation

“This umbrella OSF project serves as the official, timestamped public archive for all core intellectual property (IP), patents, peer reviews, scientific validation, and legal evidence related to the MasterMindGenesis™ invention suite (including MindAmp FX, GULF Law, HFML™, ISOTruth™, Silent Human Resonance™, AuraShield™, Tunable Reality™ and associated trademarks). All uploads are intended for legal defensibility, scholarly citation, and public transparency.

MasterMindGenesis™ — Foundational IP, Patents & Scientific Validation

“This umbrella OSF project serves as the official, timestamped public archive for all core intellectual property (IP), patents, peer reviews, scientific validation, and legal evidence related to the MasterMindGenesis™ invention suite (including MindAmp FX, GULF Law, HFML™, ISOTruth™, Silent Human Resonance™, AuraShield™, Tunable Reality™ and associated trademarks). All uploads are intended for legal defensibility, scholarly citation, and public transparency.

A retrospective health policy analysis of the development and implementation of the voluntary health insurance system in Lebanon: Learning from failure

AbstractPublic policymaking is complex and suffers from limited uptake of research evidence, particularly in the Eastern Mediterranean Region (EMR). In-depth case studies examining health policymaking in the EMR are lacking. This retrospective policy analysis aims at generating insights about how policies are being made, identifying factors influencing policymaking and assessing to what extent evidence is used in this process by using the Lebanese Voluntary Health Insurance policy as a case study. The study examined the policymaking process through a policy tracing technique that covered a period of 12 years. The study employed a qualitative research design using a case study approach and was conducted in two phases over the course of two years. Data was collected using multiple sources including: 1) a comprehensive and chronological media review; 2) twenty-two key informant interviews with policymakers, stakeholders, and journalists; and 3) a document review of legislations, minutes of meetings, actuarial studies, and official documents. Data was analyzed and validated using thematic analysis. Findings showed that the voluntary health insurance policy was a political decision taken by the government to tackle an urgent political problem. Evidence was not used to guide policy development and implementation and policy implementers and other stakeholders were not involved in policy development. Factors influencing policymaking were political interests, sectarianism, urgency, and values of policymakers. Barriers to the use of evidence were lack of policy-relevant research evidence, political context, personal interests, and resource constraints. Findings suggest that policymakers should be made more aware of the important role of evidence in informing public policymaking and the need for building capacity to develop, implement and evaluate policies. Study findings are likely to matter in light of the changes that are unfolding in some Arab countries and the looming opportunities for policy reforms

Impact of metastasectomy on progression free and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry.

753 Background: The role of metastasectomy has been in flux as treatment paradigms for management of metastatic renal cell carcinoma (mRCC) have shifted. We examined outcomes of surgical metastasectomy stratified in the setting of different mRCC risk groups. Methods: Multicenter retrospective analysis of patients from the REMARCC (REgistry of MetAstatic RCC) database. The cohort was subdivided by Motzer RCC criteria (low, intermediate, and high risk), and impact of metastasectomy was analyzed via multivariable analysis (MVA) and Kaplan Meier analyses (KMA). Primary outcome was progression free survival (PFS) and secondary outcome was overall survival (OS). Results: 438 patients (46 low risk, 262 intermediate risk, 140 high risk) with median follow-up 16 months were analyzed. Metastasectomy was performed in 18 (39%), 63 (24%), and 32 (23%) of low, intermediate and high risk groups (p=0.04). Risk groups differed significantly with respect to ECOG performance status (p&lt;0.001), metastases at diagnosis (low 1.72, intermediate 3.49, high 6.45, p&lt;0.001), hemoglobin (p&lt;0.001) and LDH (p&lt;0.001). MVA for PFS revealed age (OR=1.03, p=0.05), BMI (OR=1.05, p=0.01), and higher risk category [vs. low (referent) intermediate OR=7.4, p&lt;0.001, high OR=3.4, p=0.01] to be independent risk factors. MVA for OS revealed age (OR=1.03, p=0.02), BMI (OR=1.06, p=0.01), and higher risk category [low (referent) vs. intermediate OR=2.8, p=0.03, high OR=2.3, p=0.01] to be independent risk factors. KMA for PFS demonstrated that metastasectomy was associated with longer PFS in intermediate (24.0 vs. 6.7 months, p=0.01) but not high risk (4.2 vs. 4.0 months, p=0.58) and low risk (p=0.51) groups. KMA for OS demonstrated that metastasectomy was associated with longer median OS in the intermediate (56.9 vs. 29.3 months, p=0.01) and high risk (18.2 vs. 10.5, p=0.01), but not low risk (p=0.21) groups. Conclusions: Receipt of metastasectomy was associated with improved PFS in intermediate risk and improved OS in intermediate and high risk mRCC patients. These findings challenge prevailing assumptions about utility of metastasectomy. Further investigation is requisite to refine criteria for employment. </jats:p